Pavel Bezecny

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

Peter S Hall, Daniel Swinson, David A. Cairns et al. · JAMA Oncology · 2021 · 191 citations · Full text

Medicine, Geriatric Medicine, Oncology +14

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert H. Jones, Margherita Carucci, Angela Casbard et al. · Journal of Clinical Oncology · 2019 · 38 citations

Medicine, Oncology, Pharmacology +16